Mittal Darji, Adwait Pradhan, Sateesh Kumar Vemula, K. Kolter, Nigel Langley, Michael A. Repka
{"title":"采用Kollicoat®MAE 100P热熔挤出技术开发布洛芬缓释微丸","authors":"Mittal Darji, Adwait Pradhan, Sateesh Kumar Vemula, K. Kolter, Nigel Langley, Michael A. Repka","doi":"10.1007/s12247-023-09758-x","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>The present work was intended to develop the ibuprofen-Kollicoat<sup>®</sup> MAE 100P delayed-release pellets using hot-melt extrusion technology, which exhibits pH-dependent solubility. Ibuprofen irritates the gastric lining, so its release in the gastric environment is not desired. Conventionally, Kollicoat<sup>®</sup> MAE 100P has been used as an enteric coating polymer, and we have explored its application using hot-melt extrusion technology in our work.</p><h3>Methods</h3><p>Three different drug loadings were processed at various extrusion temperatures using HME to produce pellets of uniform size. DSC was performed to study the drug’s state, the polymer’s thermal behavior, and drug-polymer miscibility. An in vitro drug release study was performed in 0.1N HCl followed by pH 6.8 phosphate buffer to understand the ability of the polymer to impede the release of ibuprofen in the stomach. Furthermore, the lead batch was characterized by DSC, FTIR, HS-PLM, and optical microscopy to study the interaction between the drug and polymer.</p><h3>Results</h3><p>The thermogram of the pellets indicated no drug-polymer immiscibility. This work also demonstrates proof of the plasticizing ability of ibuprofen. Drug release studies showed less than 1.5% drug release in 0.1N HCl in 2 h, and complete drug release was obtained in the next 2 h in pH 6.8 phosphate buffer, indicating the delayed-release characteristics of the pellets.</p><h3>Conclusion</h3><p>This work proves that Kollicoat<sup>®</sup> MAE 100P could be used in modified-release dosage forms to attain the delayed-release pellets.</p><h3>Graphical Abstract</h3><p>Schematic representation of development of\nibuprofen delayed release pellets</p>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"18 4","pages":"1827 - 1837"},"PeriodicalIF":2.7000,"publicationDate":"2023-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of Delayed-Release Pellets of Ibuprofen Using Kollicoat® MAE 100P via Hot-Melt Extrusion Technology\",\"authors\":\"Mittal Darji, Adwait Pradhan, Sateesh Kumar Vemula, K. Kolter, Nigel Langley, Michael A. Repka\",\"doi\":\"10.1007/s12247-023-09758-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>The present work was intended to develop the ibuprofen-Kollicoat<sup>®</sup> MAE 100P delayed-release pellets using hot-melt extrusion technology, which exhibits pH-dependent solubility. Ibuprofen irritates the gastric lining, so its release in the gastric environment is not desired. Conventionally, Kollicoat<sup>®</sup> MAE 100P has been used as an enteric coating polymer, and we have explored its application using hot-melt extrusion technology in our work.</p><h3>Methods</h3><p>Three different drug loadings were processed at various extrusion temperatures using HME to produce pellets of uniform size. DSC was performed to study the drug’s state, the polymer’s thermal behavior, and drug-polymer miscibility. An in vitro drug release study was performed in 0.1N HCl followed by pH 6.8 phosphate buffer to understand the ability of the polymer to impede the release of ibuprofen in the stomach. Furthermore, the lead batch was characterized by DSC, FTIR, HS-PLM, and optical microscopy to study the interaction between the drug and polymer.</p><h3>Results</h3><p>The thermogram of the pellets indicated no drug-polymer immiscibility. This work also demonstrates proof of the plasticizing ability of ibuprofen. Drug release studies showed less than 1.5% drug release in 0.1N HCl in 2 h, and complete drug release was obtained in the next 2 h in pH 6.8 phosphate buffer, indicating the delayed-release characteristics of the pellets.</p><h3>Conclusion</h3><p>This work proves that Kollicoat<sup>®</sup> MAE 100P could be used in modified-release dosage forms to attain the delayed-release pellets.</p><h3>Graphical Abstract</h3><p>Schematic representation of development of\\nibuprofen delayed release pellets</p>\\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>\",\"PeriodicalId\":656,\"journal\":{\"name\":\"Journal of Pharmaceutical Innovation\",\"volume\":\"18 4\",\"pages\":\"1827 - 1837\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2023-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Innovation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12247-023-09758-x\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-023-09758-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Development of Delayed-Release Pellets of Ibuprofen Using Kollicoat® MAE 100P via Hot-Melt Extrusion Technology
Purpose
The present work was intended to develop the ibuprofen-Kollicoat® MAE 100P delayed-release pellets using hot-melt extrusion technology, which exhibits pH-dependent solubility. Ibuprofen irritates the gastric lining, so its release in the gastric environment is not desired. Conventionally, Kollicoat® MAE 100P has been used as an enteric coating polymer, and we have explored its application using hot-melt extrusion technology in our work.
Methods
Three different drug loadings were processed at various extrusion temperatures using HME to produce pellets of uniform size. DSC was performed to study the drug’s state, the polymer’s thermal behavior, and drug-polymer miscibility. An in vitro drug release study was performed in 0.1N HCl followed by pH 6.8 phosphate buffer to understand the ability of the polymer to impede the release of ibuprofen in the stomach. Furthermore, the lead batch was characterized by DSC, FTIR, HS-PLM, and optical microscopy to study the interaction between the drug and polymer.
Results
The thermogram of the pellets indicated no drug-polymer immiscibility. This work also demonstrates proof of the plasticizing ability of ibuprofen. Drug release studies showed less than 1.5% drug release in 0.1N HCl in 2 h, and complete drug release was obtained in the next 2 h in pH 6.8 phosphate buffer, indicating the delayed-release characteristics of the pellets.
Conclusion
This work proves that Kollicoat® MAE 100P could be used in modified-release dosage forms to attain the delayed-release pellets.
Graphical Abstract
Schematic representation of development of
ibuprofen delayed release pellets
期刊介绍:
The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories:
Materials science,
Product design,
Process design, optimization, automation and control,
Facilities; Information management,
Regulatory policy and strategy,
Supply chain developments ,
Education and professional development,
Journal of Pharmaceutical Innovation publishes four issues a year.